RxDoctor Payments Data

Amy Schreiber, MD

Family Medicine · Palmyra, PANPI 1902195654

Payments from drug & device makers

$3,512in general payments, 2019–2025

Across 217 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$665
  • Novo Nordisk$584
  • AbbVie$563
  • Pfizer$426
  • Johnson & Johnson$137
  • Amgen$126
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,512 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$87,150
Medicare patients
325
Services billed
1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$50,182
OzempicSemaglutide43$47,751
XareltoRivaroxaban89$46,389
MounjaroTirzepatide29$35,542
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$27,097
JanuviaSitagliptin Phosphate20$24,185
JardianceEmpagliflozin20$23,727
Janumet XrSitagliptin Phos/Metformin Hcl14$15,178
InvokanaCanagliflozin14$13,115
FarxigaDapagliflozin Propanediol12$10,743
MyrbetriqMirabegron20$9,697
LinzessLinaclotide12$7,510
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$5,247
Aripiprazole40$5,171
Atorvastatin Calcium418$4,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$137$59,504103 claims
PfizerEliquis$426$50,18250 claims
Novo NordiskOzempic$584$47,75143 claims
MerckJanuvia, Janumet Xr$44$39,36234 claims
Lilly USA, LLCMounjaro$63$35,54229 claims
GSKTrelegy Ellipta$665$27,09727 claims
Boehringer IngelheimJardiance$28$23,72720 claims
AstraZenecaFarxiga$57$10,74312 claims
AbbVieLinzess, Synthroid$563$10,09157 claims
Astellas Pharma US IncMyrbetriq$120$9,69720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Palmyra

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →